Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Is an Advanced Medical Process and Includes a Lot of Risks

                                                                       
Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment is used for treating this health issue.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment


  Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment is used for treating this health issue. Transthyretin amyloid cardiomyopathies result from the accumulation of transthyretin amyloid fibrils in the myocardium. The THAOS (Transthyretin Amyloidosis Outcomes Survey) is an international longitudinal observational study that includes asymptomatic patients with transthyretin mutations.

While the frequency of cardiac involvement and prognosis differ by type, there are some common characteristics. Light-chain amyloidosis is associated with an extremely high mortality rate, while wild-type ATTR amyloidosis has a much poorer outcome. Although transthyretin cardiomyopathy is rare, it is a life-threatening disease. If left untreated, patients may develop a form of heart failure known as restrictive cardiomyopathy. Hence it is needed to find out a proper transthyretin amyloid cardiomyopathy (ATTR-CM) treatment

Although transthyretin cardiomyopathy is a life-threatening, progressive, and infiltrative disease, it can be overlooked as a cause of heart failure. TTR proteins with unstable structures misfold, resulting in the deposition of amyloid fibrils in the heart and other organs. Although the disease may be rare, the diagnostic clues for it are often subtle. The key is to find the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment. In regions such as the United States, the increasing prevalence of cardiac failure has increased the research related to transthyretin amyloid cardiomyopathy (ATTR-CM) treatment. For instance, according to the U.S. Centers for Disease Control and Prevention, around 6.3 million individuals in the U.S. suffer from heart failure.

ATTR-CM can manifest as either a heritable or non-heritable disorder, and the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment is dependent on the type. The heritable form of ATTR-CM has an endemic distribution with onset between 30 and 80 years of age. The non-heritable form shows a broader prevalence of CM after the sixth decade. However, the disease is still not well understood. The best way to diagnose ATTR cardiomyopathy is through a comprehensive evaluation of the heart and the genetics of the patient.

Comments

Post a Comment

Popular posts from this blog

Label-Free Array Systems; Best Suited For Drug Discovery, Rapid Diagnosis, and Security Applications

Image
                                                                                                         Label-Free Array Systems Label-free array systems are widely used in the drug discovery process by biotechnology and pharmaceutical companies. A system works on principle of optical interferometry, impedance-based assays, and refractive index to identify and validate new molecules as the possible drug candidates. Moreover, the system helps to reduce the cost and time for drug identification and validation process. In the past few years, label-free array systems have taken center stage as an effective research tool in all major clinical drug discovery processes. Label-free array systems comprises two types of biosensors, namely optical and impedance-based biosensors, including techniques such as bio-layer interferometry, isothermal titration calorimetry, surface plasmon resonance, and others. Of which, surface plasmon resonance is the most commonly used technique. The main advantag
Read more

Rising adoption of AI to boost Smart Home as a service Market Growth

Image
Smart Home as a service Market Smart Home as a service Market by System (Lighting Control, Home Monitoring/Security, Thermostat, Smart Appliances, Video Entertainment), Channel (Retailers, OEM, E-commerce) and By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030 The global Smart Home as a Service Market is estimated to be valued at US$ 2,483.48 million in 2023, and is expected to exhibit a CAGR of 16.98 % over the forecast period, as highlighted in a new report published by Coherent Market Insights. Market Overview: Smart home as a service or also known as ShaaS is a kind of service where as a substitute of user, service provider chooses, installs, manages, upgrades, and programs smart home devices. Smart home as a service utilizes the subscription-based business designs with monthly payment from users. Competitive Landscape: Key players involved in the growth of the global Sm
Read more

Cataract Surgery Devices have significantly improved over the years with rising emphasis on the safety of the patient and accuracy of the surgery

Image
                                                          Cataract Surgery Devices Cataract surgery involves replacing the natural lens of the eye with an intraocular lens. The condition causes a cloudy vision. The natural lens of the eye has become opaque. In order to correct this problem, a person may need this procedure. The surgery is commonly known as a lens replacement. Although it is not a traumatic procedure, it can be painful and requires several sessions. However, it is not the only option for this condition. A high-frequency ultrasound device is used during cataract surgery. The surgeon will remove the lens with the use of a suction device. The surgery can be done on the day of the procedure. A temporary prescription eye shield will help to recover faster. After the procedure, the patient will still need to wear glasses or contacts. One can even start a new activity right after the surgery. The process of recovery varies depending on the specific needs and the extent of the
Read more